EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy

Nihal El Rouby iD, Christina L Aquilante, Salma A Bargal iD, Larisa H Cavallari iD, Julio D Duarte, Kelly Gunderson, Tinashe Mazhindu, Mohamed Nagy iD, Xiaoyan Nie iD, D Grace Nguyen, Jai N Patel, Todd C Skaar iD und 5 weitere

Clinical and Translational Science · 2026-01 · 19 (1)

DOI: 10.1111/cts.70466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 27.12.2025. Verfasst von Nihal El Rouby und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Fluorouracil, Antimetabolites, Antineoplastic, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluoropyrimidines are a vital component of chemotherapy regimens. Deleterious DPYD variants reduce activity of dihydropyrimidine dehydrogenase, the rate‐limiting enzyme of fluoropyrimidine catabolism, resulting in reduced fluoropyrimidine clearance and elevated risk of life‐threatening toxicities. DPYD genotype‐guided fluoropyrimidine therapy can mitigate the risk of severe life‐threatening toxicities, but adoption of testing globally has been limited. We developed a 91‐item survey investigating global DPYD implementation strategies to gain insight into common practices and successful strategies. The survey was disseminated to Pharmacogenomics Global Research Network Implementation Working Group members consisting of 54 health care sites across 15 countries. Survey responses were received from 28 sites (52%) across 9 countries. Over 80% of sites implemented, or planned to implement, a preemptive testing strategy (i.e., before a fluoropyrimidine is administered) leveraging the electronic health record (EHR) to disseminate DPYD results to providers. All sites created infrastructure to support DPYD testing (e.g., order sets, EHR decision support), but 70% of sites indicated reliance on clinicians to remember test ordering. Only 2 sites reported high DPYD testing rates (> 75%) among patients planned to receive a fluoropyrimidine. Most sites (57%) used in‐house clinical laboratories that tested for the majority of DPYD Tier 1 variants. Among sites that had implemented DPYD testing, the median turnaround time was 10 days. Few sites indicated that a high percentage (> 75%) of DPYD results were returned before fluoropyrimidine administration. Our results suggest that additional implementation strategies are needed, addressing barriers and facilitators of DPYD testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)FluorouracilAntimetabolites, AntineoplasticNeoplasmsPharmacogenomic TestingHumansElectronic Health RecordsSurveys and Questionnaires

Stichwörter der Autor:innen

DPYDfluoropyrimidinesimplementation sciencepharmacogenetics

Substanzen

Dihydrouracil Dehydrogenase (NADP)FluorouracilAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
  • St. Elizabeth Healthcare, Edgewood, Kentucky, USA.
  • Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
  • Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Center for Pharmacogenomics and Precision Medicine and Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Nihal El Rouby, Salma A Bargal, Larisa H Cavallari, Mohamed Nagy, Xiaoyan Nie, Todd C Skaar, D Max Smith, Sony Tuteja, J Kevin Hicks

Zitieren

APA

El Rouby, N., Aquilante, C. L., Bargal, S. A., Cavallari, L. H., Duarte, J. D., Gunderson, K., Mazhindu, T., Nagy, M., Nie, X., Nguyen, D. G., Patel, J. N., Skaar, T. C., Smith, D. M., Tuteja, S., van Schaik, R. H. N., Hicks, J. K., & PGRN Implementation Working Group (2026). Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy. Clinical and Translational Science, 19(1). https://doi.org/10.1111/cts.70466

Vancouver

El Rouby N, Aquilante CL, Bargal SA, Cavallari LH, Duarte JD, Gunderson K, et al. Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy. Clinical and Translational Science. 2026;19(1). doi:10.1111/cts.70466

BibTeX
@article{ElRouby2026,
  author = {El Rouby, Nihal and Aquilante, Christina L and Bargal, Salma A and Cavallari, Larisa H and Duarte, Julio D and Gunderson, Kelly and Mazhindu, Tinashe and Nagy, Mohamed and Nie, Xiaoyan and Nguyen, D Grace and Patel, Jai N and Skaar, Todd C and Smith, D Max and Tuteja, Sony and van Schaik, Ron H N and Hicks, J Kevin and PGRN Implementation Working Group, PGRN Implementation Working Group},
  title = {Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {1},
  doi = {10.1111/cts.70466}
}
Kostenlos starten →